within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC08_Canakinumab;

model Canakinumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.013888888888889e-09,
    adminDuration = 600,
    adminMass = 150 / 1000000,
    adminCount = 1,
    Vd = 0.006,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0026,
    k12 = 8.00925925925926e-09,
    k21 = 8.00925925925926e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Canakinumab</td></tr><tr><td>ATC code:</td><td>L04AC08</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>150</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>6.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.174</td><td>L/day</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Canakinumab is a human monoclonal antibody targeting interleukin-1 beta (IL-1β), used in the treatment of autoinflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (sJIA), and Still's disease. It is an approved immunosuppressive agent, primarily administered to reduce inflammation.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult and pediatric patients with autoinflammatory conditions. Data from observed clinical trials including healthy volunteers and patients with CAPS.</p><h4>References</h4><ol><li><p>Chakraborty, A, et al., &amp; Roy, S (2012). Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. <i>Clinical pharmacokinetics</i> 51(6) e1–e18. DOI:<a href=\"https://doi.org/10.2165/11599820-000000000-00000\">10.2165/11599820-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22550964/\">https://pubmed.ncbi.nlm.nih.gov/22550964</a></p></li><li><p>Chakraborty, A, et al., &amp; Howard, D (2013). Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. <i>Journal of clinical pharmacology</i> 53(12) 1240–1251. DOI:<a href=\"https://doi.org/10.1002/jcph.162\">10.1002/jcph.162</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24122883/\">https://pubmed.ncbi.nlm.nih.gov/24122883</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AC08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Canakinumab;
